prebiot
probiot
wide
studi
appli
pharmaceut
food
industri
due
health
benefit
global
prebiot
probiot
market
constantli
grow
partli
attribut
consum
awar
health
benefit
consumpt
therefor
demand
nutrit
therapeut
valu
food
product
activ
benefici
microbi
commun
enorm
impact
human
wellb
includ
host
metabol
physiolog
nutrit
immun
function
thu
consumpt
probiot
purport
maintain
balanc
gut
flora
inhibit
growth
pathogen
bacteria
consumpt
nutrient
exert
select
posit
effect
benefici
gut
bacteri
flora
ie
prebiot
anoth
usual
adopt
strategi
probiot
consid
promis
altern
antibiot
sinc
displac
harm
bacteria
variou
mechan
regard
sever
studi
explor
effect
probiot
prebiot
use
microbiota
part
bodi
treat
halitosi
suzuki
et
al
atop
dermat
wu
et
al
allergi
relat
respiratori
system
watt
et
al
restor
vagin
microbiota
gabrielli
et
al
among
other
review
focus
scientif
knowledg
regard
effect
probiot
prebiot
prevent
treatment
infecti
diseas
occur
skin
femal
urogenit
tract
respiratori
tract
probiot
defin
live
microorgan
administ
adequ
amount
confer
health
benefit
host
faowho
howev
microorgan
classifi
probiot
must
compli
guidelin
evalu
probiot
food
faowho
microorgan
biolog
genet
stabl
good
sensori
properti
low
cost
maintain
viabil
process
storag
resist
physicochem
process
food
use
food
addit
collin
gibson
prado
et
al
sander
scientif
literatur
show
differ
degre
evid
support
benefici
effect
probiot
human
health
improv
lactos
digest
reduc
symptom
lactos
intoler
reduc
intestin
ph
blood
cholesterol
produc
vitamin
b
improv
dietari
calcium
bioavail
nagpal
et
al
prado
et
al
addit
probiot
inhibit
onset
allerg
diseas
prevent
treat
ischem
heart
syndrom
faowho
howev
health
benefit
requir
addit
studi
cancer
prevent
treatment
acut
diarrheal
diseas
anticariogen
properti
kechagia
et
al
nagpal
et
al
gibson
roberfroid
introduc
prebiot
concept
gibson
roberfroid
recent
prebiot
defin
substrat
select
util
host
microorgan
confer
health
benefit
new
definit
allow
inclus
noncarbohydr
substanc
applic
bodi
site
gastrointestin
tract
definit
also
appli
prebiot
anim
use
gibson
et
al
prebiot
activ
ingredi
evalu
seri
vitro
vivo
assay
follow
methodolog
recent
propos
bajuri
et
al
vitro
method
includ
vitro
digest
vitro
ferment
vivo
method
includ
anim
studi
human
clinic
studi
analysi
ferment
product
valid
vitro
vivo
studi
bestknown
frequent
studi
prebiot
inulintyp
fructan
includ
nativ
inulin
oligofructos
synthet
fructooligosaccharid
fo
exampl
galactooligosaccharid
go
arabinos
raffinos
lactulos
pyrodextrin
soya
oligosaccharid
xylooligosaccharid
de
souza
et
al
gibson
fuller
pineiro
et
al
extract
natur
sourc
chicori
root
dahlia
tuber
artichok
yacon
agav
garlic
onion
asparagu
leek
flaxse
soya
bean
well
human
breast
milk
cow
milk
campo
et
al
gibson
et
al
gomez
et
al
configur
glycosid
bond
prebiot
resist
hydrolysi
intestin
acid
digest
enzym
therefor
prebiot
degrad
upper
region
gastrointestin
tract
reach
colon
intact
degrad
gut
microbiota
produc
acet
propion
butyr
lactic
acid
well
gass
et
al
develop
pharmaceut
food
product
contain
prebiot
substanc
probiot
microorgan
aim
modul
gut
microbiota
promin
strategi
control
treat
infecti
diseas
product
call
synbiot
due
synergist
effect
pre
probiot
theori
synbiot
product
improv
surviv
implant
live
probiot
gastrointestin
tract
select
stimul
growth
andor
metabol
activ
limit
number
healthpromot
microorgan
pandey
et
al
probiot
use
synbiot
formul
usual
includ
strain
belong
lactobacillu
bifidobacterium
enterococcu
streptococcu
genera
main
prebiot
formul
includ
inulin
fo
differ
sourc
go
xylos
oligosaccharid
transgalactooligosaccharid
lactulos
lactilol
lactosucros
markowiak
pandey
et
al
sekhon
jairath
effect
synbiot
relationship
human
health
address
sever
studi
aim
evalu
effect
synbiot
product
metabol
statu
patient
type
diabet
mellitu
dm
tajadadiebrahimi
et
al
studi
focus
healthrel
qualiti
life
irrit
bowel
syndrom
symptom
et
al
weight
loss
mainten
obes
patient
sanchez
et
al
glucos
metabol
gut
microbiom
liu
et
al
studi
suggest
synbiot
relationship
would
also
use
part
human
bodi
benefici
microbi
commun
host
also
exist
luoto
et
al
suzuki
et
al
wu
et
al
although
probiot
wide
studi
mechan
action
prevent
treatment
bacteri
infect
part
human
bodi
skin
femal
urogenit
tract
respiratori
tract
far
unknown
howev
postul
similar
mechan
intestin
epithelium
may
exist
tapiovaara
et
al
shown
fig
probiot
improv
human
health
oral
consumpt
local
applic
figur
also
outlin
possibl
mechan
probiot
action
skin
femal
urogenit
tract
respiratori
tract
includ
modul
system
immun
function
competit
exclus
harm
microorgan
product
antimicrobi
substanc
growth
substrat
inhibit
bacteri
toxin
product
among
other
bermudezbrito
et
al
gogineni
et
al
markowiak
rahmati
roudsari
et
al
gener
studi
field
skin
diseas
refer
mainli
effect
probiot
prebiot
ingest
effect
topic
applic
bare
investig
lee
et
al
innov
line
cosmet
recent
develop
socal
prebiot
cosmet
strategi
rebal
composit
skin
microflora
inhibit
growth
transient
pathogen
speci
promot
growth
benefici
bacteria
resid
microorgan
krutmann
alghazzewi
tester
show
konjac
glucomannan
hydrolys
probiot
strain
lactobacillu
acidophilu
lactobacillu
casei
lactobacillu
plantarum
lactobacillu
gasseri
lactococcu
lacti
ssp
lacti
inhibit
p
acn
nctc
growth
vitro
bateni
et
al
determin
spray
formul
contain
konjac
glucomannan
hydrolys
wv
significantli
improv
skin
health
acn
vulgari
young
women
twenti
forti
day
treatment
kang
et
al
studi
therapeut
effect
p
acn
lotion
prepar
concentr
powder
cbt
cellfre
cultur
supernat
enterococcu
faecali
random
doubleblind
placebocontrol
trial
includ
patient
placebo
group
test
group
diagnos
acn
vulgari
face
patient
year
old
instruct
appli
thin
layer
cbt
lotion
twice
day
affect
area
result
show
lotion
significantli
p
reduc
inflammatori
lesion
rel
placebo
lotion
muizzuddin
et
al
observ
reduct
acn
lesion
size
clinic
studi
l
plantarum
extract
howev
size
reduct
occur
lope
et
al
determin
vitro
assay
propioniferax
innocua
l
acidophilu
lactobacillu
delbrueckii
l
acidophilu
lactobacillu
paracasei
bifidobacterium
lacti
bifidobacterium
animali
exhibit
highest
adhes
valu
human
keratin
addit
probiot
p
innocua
significantli
p
reduc
adher
p
acn
hand
l
acidophilu
l
delbrueckii
l
acidophilu
l
paracasei
b
animali
exhibit
import
zone
inhibit
mm
p
acn
lope
et
al
also
found
probiot
assay
decreas
p
acn
biofilm
format
et
al
studi
effect
lotion
contain
heattreat
lactobacillu
johnsonii
ncc
aureu
colon
ad
patient
openlabel
multicent
studi
consist
follow
two
stage
assess
aureu
sampl
quantif
method
evalu
cosmet
lotion
contain
heattreat
probiot
first
part
studi
includ
patient
second
part
studi
includ
patient
carrier
aureu
start
studi
clinic
visibl
lesion
day
patient
male
femal
age
year
diagnos
ad
mildtomoder
sever
instruct
appli
probiot
lotion
cfug
lesion
skin
twice
daili
week
applic
probiot
lotion
control
aureu
colon
associ
local
clinic
improv
score
atop
dermat
index
scorad
rosacea
associ
certain
gastrointestin
diseas
small
intestin
bacteri
overgrowth
sibo
irrit
bowel
syndrom
other
egeberg
et
al
howev
possibl
pathogen
link
unknown
egeberg
et
al
furthermor
sibo
treatment
antibiot
lead
erad
rosacea
maintain
nine
month
parodi
et
al
manzhalii
et
al
evalu
probiot
therapi
intestinalborn
dermatos
studi
placebo
group
patient
receiv
vegetarian
diet
convent
topic
dermatos
therapi
ie
ointment
tetracyclin
steroid
retinoid
addit
test
group
patient
receiv
addit
therapi
consist
oral
escherichia
coli
nissl
administr
one
capsul
day
capsul
daili
follow
month
contain
live
bacteria
cfu
administr
probiot
capsul
significantli
p
amelior
dermatos
rosacea
acn
caus
complet
recoveri
contrast
placebo
group
improv
associ
signific
increas
iga
level
serum
cyokim
suppress
daili
consumpt
ferment
milk
contain
lactobacillu
bulgaricu
streptococcu
thermophilu
improv
clinic
grade
acn
week
clinic
studi
kim
et
al
condit
improv
lactoferrin
antiinflammatori
milk
protein
addit
ie
lactoferrinenrich
ferment
milk
decreas
acn
vulgari
reduc
triacylglycerol
skin
surfac
lipid
addit
neither
probioticfer
milk
produc
alter
skin
hydrat
ph
jung
et
al
evalu
whether
probiot
could
work
synergist
antibiot
treat
inflammatori
acn
reduc
side
effect
antibiot
administr
openlabel
studi
consid
fortyf
femal
age
year
mild
moder
acn
vulgari
patient
randomli
assign
one
follow
three
group
probiot
group
advis
take
one
capsul
morn
even
minocyclin
group
advis
take
antibiot
dinner
patient
combin
treatment
probiot
plu
antibiot
instruct
take
probiot
least
h
antibiot
dosag
addit
patient
receiv
standard
topic
acn
medic
facial
cleaner
appli
twice
daili
probiot
capsul
includ
l
acidophilu
l
delbrueckii
sp
bulgaricu
cfucapsul
bifidobacterium
bifidum
billon
cfucapsul
clinic
evalu
perform
baselin
followup
visit
week
treatment
initi
first
week
patient
demonstr
signific
p
improv
total
lesion
count
week
total
lesion
count
group
combin
treatment
decreas
significantli
compar
two
group
jung
et
al
show
probiot
reduc
potenti
side
effect
antibiot
use
also
augment
antibiot
therapi
recent
decad
incid
ad
children
increas
chronic
diseas
caus
itchi
skin
chamlin
et
al
sever
studi
evalu
effect
probiot
combin
prebiot
howev
result
still
inconclus
may
depend
sever
diseas
probiot
appli
wu
et
al
studi
effect
lactobacillu
salivariu
fo
infant
ad
sixti
children
age
year
receiv
two
capsul
contain
either
l
salivariu
plu
fo
treatment
fo
control
daili
week
ad
intens
decreas
significantli
p
children
administ
synbiot
treatment
compar
control
group
studi
evalu
effect
probiot
treatment
children
ad
forti
pediatr
patient
age
year
assign
test
placebo
group
group
consum
two
bag
day
total
eight
week
test
bag
contain
cfu
four
type
probiot
bacteria
b
bifidum
l
acidophilu
l
casei
l
salivariu
placebo
bag
contain
skim
milk
powder
dextros
combin
probiot
strain
effect
reduc
scorad
treatment
ad
pediatr
patient
et
al
recent
effect
l
plantarum
also
evalu
children
mild
moder
ad
random
doubleblind
placebocontrol
trial
probiot
function
evalu
abil
decreas
scorad
level
serum
immunoglobulin
studi
twentytwo
ad
patient
age
year
includ
test
group
girl
boy
receiv
microencapsul
probiot
l
plantarum
cfuday
placebo
group
girl
boy
receiv
skim
milk
twice
daili
week
scorad
reduct
test
group
significantli
p
higher
placebo
group
end
studi
level
p
p
p
significantli
lower
probiot
group
placebo
group
ige
level
significantli
chang
thu
l
plantarum
abl
reduc
clinic
symptom
children
diagnos
ad
therefor
potenti
treat
diseas
prakoeswa
et
al
cabana
et
al
evalu
effect
daili
l
rhamnosu
gg
supplement
first
month
life
decreas
eczema
incid
potenti
earli
marker
asthma
intervent
infant
receiv
daili
dose
l
rhamnosu
gg
cfu
inulin
mg
control
infant
receiv
inulin
mg
alon
result
show
earli
probiot
supplement
first
month
life
prevent
develop
either
eczema
asthma
year
age
infant
high
risk
allerg
diseas
metaanalysi
effect
probiot
andor
prebiot
prevent
eczema
infant
determin
probiot
synbiot
may
reduc
eczema
incid
infant
year
old
system
sensit
chang
follow
probiot
administr
danq
et
al
metaanalysi
effect
prenat
postnat
probiot
supplement
prevent
infantil
childhood
eczema
establish
pool
rel
risk
studi
confid
interv
author
conclud
use
probiot
supplement
pregnanc
andor
infanc
significantli
reduc
eczema
incid
mansfield
et
al
anoth
metaanalysi
cuellogarcia
et
al
evalu
use
probiot
prevent
allergi
ad
eczema
studi
includ
random
control
trial
minimum
followup
week
compar
type
probiot
placebo
select
studi
includ
pregnant
women
breastfeed
mother
infant
children
studi
consid
use
probiot
newborn
infant
preschool
schoolag
children
year
age
metaanalysi
show
use
probiot
pregnant
women
breastfeed
mother
andor
given
infant
reduc
risk
eczema
infant
howev
certainti
evid
low
low
risk
bia
inconsist
imprecis
result
indirect
avail
inform
addit
evid
support
effect
allergi
nutrit
statu
incid
advers
effect
recent
yu
et
al
evalu
whether
clinic
data
support
use
oral
topic
probiot
certain
dermatolog
diseas
result
show
clinic
trial
exist
evalu
util
probiot
prevent
treatment
dermatolog
diseas
except
ad
studi
investig
oral
probiot
administr
util
topic
probiot
includ
skin
commens
howev
oral
topic
probiot
appear
effect
treatment
certain
inflammatori
skin
diseas
zeng
et
al
compar
efficaci
nonantibiot
sucros
gel
antibiot
metronidazol
gel
treatment
bv
studi
consid
subject
clinic
diagnos
bv
patient
appli
gel
twice
daili
five
consecut
day
treatment
therapeut
cure
rate
sucros
metronidazol
placebo
gel
group
day
respect
second
evalu
day
treatment
show
cure
rate
sucros
metronidazol
placebo
gel
group
respect
accord
result
research
suggest
sucros
gel
restor
normal
vagin
flora
use
novel
treatment
bv
moreov
sucros
gel
carri
less
risk
induc
pathogen
bacteriaresist
variant
current
use
antibiot
includ
metronidazol
author
argu
sucros
gel
metronidazol
gel
differ
mechan
action
treat
bv
treatment
sucros
gel
mediat
shift
vagin
bacteri
flora
therebi
promot
growth
lactobacilli
turn
gener
lactic
acid
reduc
vagin
ph
secret
antibacteri
substanc
inhibit
adhes
replic
pathogen
anaerob
bacteria
contrast
metronidazol
gel
appear
inhibit
growth
pathogen
bacteria
benefici
lactobacilli
howev
research
believ
lactobacillu
recov
faster
pathogen
bacteria
metronidazol
gel
treatment
complet
lactobacillu
resist
metronidazol
anaerob
bacteria
hemmerl
et
al
evalu
colon
effici
safeti
toler
accept
l
crispatu
lactinv
administ
vagin
applic
phase
lactinv
random
doubleblind
placebocontrol
trial
premenopaus
women
diagnos
bv
twentyfour
women
age
year
random
test
control
group
test
group
women
receiv
lactinv
cfudos
l
crispatu
control
group
women
receiv
placebo
initi
consecut
day
follow
weekli
applic
two
week
women
return
evalu
day
result
show
l
crispatu
colon
eleven
women
test
group
day
day
preexist
endogen
lactobacillu
flora
baselin
line
influenc
colon
l
crispatu
addit
women
follow
protocol
dose
recommend
time
better
colon
use
lower
dose
lactinv
final
product
well
toler
accept
cost
et
al
evalu
efficaci
safeti
intravagin
prebiot
gel
balanc
recoveri
vagin
flora
women
previous
treat
bv
doubleblind
parallel
placebocontrol
random
clinic
trial
includ
premenopaus
nonpregn
women
age
year
patient
confirm
bv
receiv
oral
antibiot
treatment
metronidazol
day
test
group
patient
random
receiv
gel
insid
small
tube
contain
ml
product
glucooligosaccharidesalpha
prebiot
equival
minimum
mg
oligosaccharid
trifolium
pratens
extract
meanwhil
control
group
patient
receiv
placebo
gel
without
activ
ingredi
intravaginalgel
selfadminist
day
consecut
day
result
show
antibiot
treatment
signific
p
differ
group
normal
vagin
flora
complet
restor
day
treatment
women
receiv
prebiot
treatment
normal
vagin
flora
women
control
group
complet
restor
normal
vagin
flora
day
treatment
women
treat
prebiot
gel
maintain
normal
vagin
flora
wherea
placebo
group
complet
restor
vagin
flora
efficaci
oral
administ
capsul
contain
probiot
l
rhamnosu
l
reuteri
evalu
random
doubleblind
multicentr
placebocontrol
trial
includ
women
older
year
age
diagnos
vagin
infect
vujic
et
al
test
group
women
placebo
group
women
receiv
either
two
probiot
capsul
contain
cfu
lactobacillu
strain
two
placebo
capsul
per
day
week
women
underw
two
gynecolog
examin
week
studi
differ
group
signific
p
fortyfour
day
initi
visit
vagin
microbiota
restor
women
probiot
group
compar
women
placebo
group
addit
week
followup
normal
vagin
microbiota
still
present
half
women
probiot
group
compar
onefifth
placebo
group
p
gill
et
al
studi
effect
oral
probiot
food
supplement
maintain
restor
normal
vagin
microbiota
pregnanc
three
hundr
twenti
women
less
complet
week
pregnanc
particip
studi
patient
consum
probiot
capsul
contain
l
rhamnosu
l
reuteri
cfu
strain
per
capsul
daili
result
show
oral
probiot
may
suitabl
implement
antenat
care
effect
vagin
health
midgest
recent
laue
et
al
evalu
effect
yoghurt
contain
lactobacillu
strain
bv
singlecent
doubleblind
placebocontrol
random
clinic
trial
two
parallel
arm
strain
isol
healthi
pregnant
women
select
acidif
capac
product
glycogen
util
bile
salt
toler
pathogen
inhibit
thirtysix
femal
volunt
select
reproduct
age
year
stabl
menstrual
cycl
postmenopaus
women
diagnos
bv
test
group
patient
receiv
yoghurt
gdaili
contain
live
strain
l
crispatu
l
gasseri
l
rhamnosu
l
jensenii
placebo
group
patient
receiv
chemic
acidifi
milk
gdaili
without
bacteri
strain
patient
treat
oral
metronidazol
day
mgdaili
start
treatment
women
consum
twice
daili
either
yoghurt
placebo
week
week
intervent
bv
test
group
vs
placebo
group
addit
intak
yoghurt
contain
lactobacillu
strain
improv
recoveri
rate
bv
symptom
vagin
microbi
pattern
recent
studi
evalu
probiot
capac
saccharomyc
cerevisia
cncm
modul
express
pathogen
determin
candida
albican
vivo
vagin
candidiasi
experiment
infect
mice
besid
administr
cerevisia
evalu
influenc
number
function
landmark
sign
inflamm
host
gener
studi
determin
daili
intravagin
administr
cerevisia
cncm
lead
suppress
sever
fungal
compon
play
critic
role
fungal
virul
c
albican
vagin
level
cerevisia
modul
express
aspartyl
proteinas
well
hyphal
growthassoci
gene
vagin
caviti
probiot
effect
host
probiot
suppress
neutrophil
influx
caus
fungu
vagina
mice
like
relat
lower
cytokin
associ
inflammatori
respons
product
inhibit
aspartyl
proteinas
express
besid
evid
cytotox
effect
either
probiot
use
vivo
vagin
epitheli
cell
organ
architectur
vitro
human
vagin
epithelium
gabrielli
et
al
handalishi
et
al
compar
efficaci
vagin
administ
probiot
vagin
tampon
oral
metronidazol
treatment
bv
singl
blind
random
clinic
trial
includ
healthi
women
diagnos
bv
patient
age
year
randomli
assign
two
group
antibiot
probiot
group
antibiot
group
patient
receiv
oral
metronidazol
mg
twice
daili
day
probiot
group
patient
use
lactobacilliimpregn
vagin
tampon
day
menstruat
probiot
group
significantli
lower
incid
discharg
metronidazol
group
p
higher
cure
rate
metronidazol
group
differ
signific
p
verdenelli
et
al
evalu
effect
probiot
suppositori
gin
vagin
health
studi
includ
appar
healthi
women
age
year
instruct
receiv
daili
day
probiot
suppositori
gin
contain
least
cfu
viabl
lactobacilli
combin
l
rhamnosu
imc
l
paracasei
imc
women
examin
three
time
studi
result
reveal
presenc
two
strain
origin
gin
women
visit
visit
addit
probiot
suppositori
welltoler
advers
effect
signific
chang
regist
ph
visit
metaanalysi
evalu
efficaci
lactobacillu
found
probiot
strain
lactobacillu
safe
effect
prevent
recurr
uti
adult
women
howev
random
clinic
trial
requir
provid
definit
recommend
sinc
patient
contribut
data
metaanalysi
grin
et
al
schwenger
et
al
evalu
potenti
therapeut
advantag
probiot
metaanalysi
prevent
uti
suscept
patient
term
morbid
mortal
compar
placebo
prophylact
intervent
metaanalysi
show
signific
reduct
p
risk
recurr
symptomat
bacteri
uti
patient
treat
probiot
placebo
furthermor
risk
reduct
recurr
symptomat
bacteri
uti
insignific
probiot
antibiotictr
patient
studi
particip
rr
ci
howev
benefit
exclud
data
deriv
small
studi
poor
methodolog
report
recent
metaanalysi
three
doubleblind
random
clinic
trial
evalu
effect
oral
administr
mixtur
four
lactobacillu
strain
l
crispatu
lbv
dsm
l
gasseri
lbv
dsm
l
jensenii
lbv
dsm
l
rhamnosu
dsm
vagin
dysbiosi
select
clinic
trial
includ
maletofemal
transsexu
women
neovagina
women
bacteri
vaginosi
postmenopaus
breast
cancer
patient
receiv
chemotherapi
metaanalysi
show
oral
intak
probiot
product
contain
lactobacillu
strain
either
yoghurt
capsul
form
may
improv
microbi
pattern
differ
form
vagin
dysbiosi
de
vrese
et
al
king
et
al
studi
effect
probiot
durat
ill
healthi
children
adult
develop
common
acut
respiratori
infect
metaanalysi
includ
twenti
random
control
trial
vari
durat
compar
lactobacillu
andor
bifidobacterium
strain
consum
oral
placebo
untreat
appar
healthi
children
adult
develop
acut
rti
period
trial
ten
trial
investig
probiot
use
children
age
year
ten
conduct
adult
age
year
two
conduct
elderli
freeliv
adult
metaanalysi
determin
probiot
consumpt
significantli
reduc
durat
ill
episod
number
day
ill
per
person
number
day
absent
day
careworkschool
hao
et
al
evalu
probiot
effect
prevent
acut
urt
infect
random
control
trial
exclud
crossov
studi
due
potenti
residu
treatment
effect
particip
children
adult
age
exclud
vaccin
influenza
acut
urti
within
last
month
take
immunestimul
medic
undertak
abnorm
physic
exercis
known
congenit
acquir
immun
defect
allergi
trial
includ
differ
type
probiot
usual
compar
placebo
metaanalysi
show
compar
placebo
probiot
may
benefici
prevent
acut
urt
infect
peopl
age
howev
qualiti
evid
low
low
studi
small
sampl
size
qualiti
method
unsatisfactori
studi
contrast
anoth
metaanalysi
determin
probiot
consumpt
appear
feasibl
way
decreas
rti
incid
children
newborn
year
wang
et
al
laursen
hojsak
evalu
strainspecif
probiot
effect
rti
children
attend
day
care
metaanalysi
includ
fifteen
random
control
trial
children
day
care
set
age
month
year
twelv
random
control
trial
high
divers
report
outcom
show
l
rhamnosu
gg
may
moder
effect
reduc
rti
durat
b
animali
ssp
lacti
effect
rti
durat
absenc
day
care
besid
potenti
effect
probiot
strain
combin
imposs
evalu
due
limit
avail
data
seri
commerci
product
contain
prebiot
andor
probiot
avail
market
complementari
approach
manag
infect
occur
skin
femal
urogenit
system
respiratori
tract
strengthen
immun
system
among
other
tabl
fig
probiot
andor
prebiot
benefici
prevent
treat
certain
infecti
diseas
skin
femal
urogenit
tract
respiratori
tract
evid
suggest
probiot
consumpt
decreas
presenc
eczema
children
mother
consum
probiot
pregnanc
lactat
women
probiot
consumpt
effect
prevent
recurr
urinari
tract
infect
consumpt
synbiot
product
reduc
respiratori
tract
infect
durat
sever
howev
vitro
vivo
clinic
studi
present
certain
shortcom
wide
varieti
probiot
consid
studi
make
difficult
identifi
individu
effect
probiot
strain
hand
studi
lack
standard
number
patient
volunt
requir
trial
small
costeffect
probiot
anoth
factor
analyz
issu
mean
inform
report
current
literatur
limit
evid
inconclus
howev
sever
probiot
prebiot
product
aim
improv
consum
qualiti
life
alreadi
market
lafti
other
advanc
nextgener
analyt
tool
enabl
explor
specif
probiot
may
posit
affect
health
immun
system
cognit
mental
health
among
other
moreov
advanc
studi
relat
microbiom
sequenc
individu
differ
state
activ
result
identif
bacteria
associ
peak
perform
recoveri
enabl
identif
specif
probiot
promot
recoveri
energi
metabol
novel
probiot
strain
recov
lipid
metabol
reduc
symptom
psycholog
distress
pregnanc
posit
impact
children
behavior
cognit
emot
develop
enhanc
perform
athlet
among
other
therefor
welldefin
multidisciplinari
clinic
studi
must
develop
recent
public
open
new
line
research
novel
probiot
synbiot
formul
prolong
longev
mechan
axi
commun
relat
chronic
diseas
manag
show
still
mani
research
question
answer
hypothes
confirm
regard
benefit
probiot
health
qualiti
life
